Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akoya Biosciences Inc (NQ: AKYA )

5.980 +0.280 (+4.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 69,872
Open 5.780
Bid (Size) 5.780 (1)
Ask (Size) 6.400 (1)
Prev. Close 5.700
Today's Range 5.644 - 6.080
52wk Range 5.270 - 16.57
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Akoya Reports Record Revenue in the First Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
From Akoya Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-35.77%
-35.77%
1 Month
-17.17%
-17.17%
3 Month
-49.11%
-49.11%
6 Month
-53.54%
-53.54%
1 Year
-49.58%
-49.58%

More News

Read More
Akoya Biosciences Marks Milestone Achievement with Shipment of 1,000th Spatial Biology Instrument
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Introduces PhenoCode Discovery Panels to Simplify PhenoCycler-Fusion Workflow
From Akoya Biosciences, Inc.
Via GlobeNewswire
Looking Into Akoya Biosciences's Return On Capital Employed
Via Benzinga
A Preview Of Akoya Biosciences's Earnings
Via Benzinga
Akoya Biosciences and Enable Medicine Introduce Cloud Platform to Power Faster Analysis of PhenoCycler-Fusion Data
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Report First Quarter 2023 Financial Results on May 8th, 2023
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Announces Leadership Transition
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Reports Record Revenue in the Fourth Quarter of 2022 and Provides Full Year 2023 Revenue Guidance
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2022
From Akoya Biosciences, Inc.
Via GlobeNewswire
Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
From Agilent Technologies Inc.
Via Business Wire
Akoya to Participate at 41st Annual J.P. Morgan Healthcare Conference
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Showcases Latest Spatial Biology Innovations at Virtual Spatial Day
From Akoya Biosciences, Inc.
Via GlobeNewswire
Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Akoya Reports Record Revenue with 40% YoY Growth in the Third Quarter and Raises Full Year 2022 Revenue Guidance
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy
From Akoya Biosciences, Inc.
Via GlobeNewswire
Preview: Akoya Biosciences's Earnings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
Via Benzinga
Akoya to Participate at Three Upcoming Investor Conferences
From Akoya Biosciences, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.